Keywords: Amgen, Nplate, GlaxoSmithKline, Promacta, USA, FDA, REMS requirements, Thrombocytopenia

FDA eases REMS requirements for Amgen’s Nplate and GSK’s Promacta

Article | 07 December 2011

Print This

The US Food and Drug Administration says that an agency initiated review of the current information has determined that, while ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in